Furthermore, we demonstrated that the NEAT1 KD effect in HMCLs is synergic with proteasome inhibitors (bortezomib and carfilzomib) or alkylating agent (melphalan) treatments, indicating that NEAT1 silencing triggers a general sensitizing effect to anti-MM (multiple myeloma) drugs. Here, NEAT1 is linked to plasma cell myeloma.